Back to news

Pivotal to collaborate with Checkpoint Therapeutics on a study in patients with cutaneous squamous cell carcinoma

  • Global trial has recently expanded to Western Europe with the first European sites now initiated
  • Collaboration will enable patients in Europe to access PD-L1 inhibitor to treat cSCC not amenable for local treatments



Forward‐Looking Statements




Ms. Natalia Farr

Thank you for
getting in touch
Go back to website